PICO

Population (P): Pediatric population (0–17 years) with immune thrombocytopenia (ITP) in the United States

Intervention (I): Not applicable

Comparison (C): Not applicable

Outcome (O): Annual incident and prevalent cases of ITP from 2025 to 2050.

Bibliography

1) Shaw, J., Kilpatrick, K., Eisen, M., & Tarantino, M. (2020). The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States. *Platelets*, *31*(3), 307–314. https://doi.org/10.1080/09537104.2019.1635687
2) Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012 Sep;87(9):848-52. doi: 10.1002/ajh.23262. Epub 2012 Jun 5. PMID: 22674643; PMCID: PMC3429719
3) Weycker D, Hanau A, Hatfield M, Wu H, Sharma A, Bensink ME, Chandler D, Grossman A, Tarantino M. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. J Med Econ. 2020 Feb;23(2):184-192. doi: 10.1080/13696998.2019.1669329. Epub 2019 Oct 9. PMID: 31547724.
4) FEUDJO-TEPIE, M.A., ROBINSON, N.J. and BENNETT, D. (2008), Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. Journal of Thrombosis and Haemostasis, 6: 711-712. https://doi.org/10.1111/j.1538-7836.2008.02911.x
5) Watts, Raymond G. "Idiopathic Thrombocytopenic Purpura: A 10-Year Natural History Study at the Childrens Hospital of Alabama." *Clinical Pediatrics*, vol. 43, no. 8, 2004, pp. 691-702. https://doi.org/10.1177/000992280404300802.
6) Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006 Nov;4(11):2377-83. doi: 10.1111/j.1538-7836.2006.02147.x. Epub 2006 Jul 27. PMID: 16869934.